augmented effector T cell responses and abrogation of transplant tolerance. Am J Transplant 2014 14: 1791-805.

2. 学会発表

1) Akbar SM, Chen S, Mahtab MA, Hiasa Y. Comparative immune modulatory capacities of HBsAg, HBcAg, and HBsAg/HBcAg and their utility for development of therapeutic vaccines. 23rd Conference of the Asian Pacific Association for the Study of the Liver, March 12-15, 2014, Brisbane, Australia

2) Akbar SM, Chen S, Mahtab MA, Hiasa Y. Myeloid-derived suppressor cells and dendritic cells for impaired response to vaccine in mice with nonalcoholic fatty liver disease. 49th Annual Meeting of the European Association for the Study of the Liver. April 9-13, 2014, London, UK

3) Yoshida O, Thomson AW, et al. DAP12 deficiency in liver allografts enhances donor DC migration, host alloimmunity and breaks liver transplant tolerance. Immunology 2014, May 2-6, 2014, Pittsburgh, USA

4) Akbar SM, Al-Mahtab M, Hiasa Y. A phase III clinical trial with HBsAg/HBcAg-based therapeutic vaccine in patients with chronic hepatitis B. 24th Annual Meeting of the Japanese Association of Antiviral Therapy, May 7-9, 2014, Yamanashi, Japan

5) Akbar SM, Al-Mahtab M, 日浅陽一. B型肝炎に対するHBs抗原およびHBc抗原ワクチン治療の第III相臨床試験－ペグインターフェロン治療との比較および免疫治療効果－, 第50回日本肝臓学会総会, 2014.5.29-30, 東京.

6) Yoshida O, Thomson AW, et al. CD39 is critical for inducing tolerance in murine allogeneic liver transplantation. 2014 World Transplant Congress, June 26-31, 2014, San Francisco, USA

7) Nishida N, Hiasa Y, et al. Associations of HLA-DPB1 with CHB infection and HBV related HCC in Asia. 65th Annual Meeting of American Association for the Study of Liver Diseases. November 7-11, 2014, Boston, USA

8) Akbar SM, Al-Mahtab M, Aguilar J, Hiasa Y. Immune modulatory antiviral drug versus HBV antigen-specific immune therapy in chronic hepatitis B: Lessons from laboratory benches and phase III clinical trials in patient's bedsides. The 2nd Japan-Italy Liver Workshop 'Hepatitis, Steatosis and Hepatocellular Carcinoma: molecular basis and clinical links, November 18-19, 2014, Miyajima, Japan

9) Akbar SM, Abe M, Al-Mahtab M, Hiasa Y, Chen S. Myeloid-derived suppressor cells, a new entity, capable of regulating antigen-specific and T-cell based immunity in chronic HBV infection. The 11th JSH Single Topic Conference, November 20-21, 2014, Hiroshima, Japan

10) Akbar SM, Hiasa Y, Al-Mahtab M, Aguilar JC, Mishiro S. One year post treatment, drug-free follow up of a phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg in patients with chronic hepatitis B. The 11th JSH Single Topic Conference, November 20-21, 2014, Hiroshima, Japan

G. 知的所有権の出願・取得状況

特になし

Ⅲ．研究成果の刊行に関する一覧表

別紙4

研究成果の刊行に関する一覧表レイアウト（参考）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
徳本良雄、利光久美子、日浅陽一	慢性肝炎	稲垣暢也 長嶋一昭 幣憲一郎	実践！ケースに学ぶ 栄養管理・食事指導 エキスパートガイド	南山堂	東京	2015	118〜121
日浅陽一	肝臓疾患の最近のトピックス	日浅陽一	診断と治療	診断と治療社	東京	2014	1600 〜 1605

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Amako Y. et al （小原）	Hepatitis C virus attenuates mitochondrial lipid β-oxidation by down-regulating mitochondrial trifunctional protein expression.	J. Virology			in press
Sato S. et al （小原）	The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factorfor Hepatitis B Virus.	Immunity	42	123-32	2015
Ezzikouri S. et al. （小原）	Inhibitory Effects of Pycnogenol® on Hepatitis C Virus Replication.	Antiviral Research	113C	93-102	2015
Tsukiyama-Kohara K. et al. （小原）	Tupaia belangeri as anExperimental Animal Model for Viral Infection.	Experimental Animal	63	367-74	2014

Lai C-K. et al. (小原)	Nonstructural Protein 5A Is Incorporated into Hepatitis C Virus Low-Density Particle through Interaction with Core Protein and Microtubules during Intracellular Transport.	PLoS ONE	9	e99022	2014
Munakata T. et al. (小原)	Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.	Antiviral Research	108	79-87	2014
Arai M. et al. (小原)	Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.	Biochem Biophys Res Commun.	448	56-62	2014
Watanabe T. et al. (小原)	In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus.	Scientific Reports	23	4:4750	2014
Kasama Y. et al. (小原)	B-cell-intrinsic Hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-kB signaling.	PLoSONE	9	e91373	2014
Ezzikouri S. et al. (小原)	Recent insights into hepatitis B virus-host interactions.	J Medical Virology	86	925-32	2014
Yasui F. et al. (小原)	Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus.	Virology	454-455	157-68	2014
Ogiwara H. et al. (小原)	Histopathological evaluation of the diversity of cells susceptible to H5N1 virulent avian influenza virus	American Journal of Pathology	184	171-83	2014

Okabayashi S. et al. （保富）	Diabetes mellitus accelerates Aβ pathology in brain accompanied by enhanced GAβ generation in nonhuman primates.	PLos One			in press
Onishi M. et al. （保富）	Hydroxypropyl-β-cyclod extrin spikes local inflammation that induce Th2 and Tfh responses to the coadministered antigen.	J.Immunol			in press
Fukuyama Y. et al. （保富）	Nanogel-based pneumococcal surface protein Anasal vaccine induces microRNA-associated Th17 cell responses withneutralizing antibodies against Streptococcus pneumonia in macaques.	Mucosal Immunology	E-pub		2015
Watanabe K. et al. （保富）	Recombinant Ag85B vaccine by taking advantage of characteristics ofhuman parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses byintranasal immunization.	Vaccine	32	1727-1735	2014
Kobiyama K. et al. （保富）	Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.	Proc. Natl. Acad Sci.USA	111	3086-3091	2014
Tsujimura Y. et al. （保富）	Effects of Mycobacteriamajor secretion protein,Ag85B, on allergic inflammation in the lung.	Plos One	E-pub		2014

Saito N. et al. （保富）	CD4(+) T cells modified by the endoribonuclease MazF are safe and can persist in SHIV-infected rhesus macaques.	Mol. Ther. Nucleic Acids	E-pub		2014
Machino-Ohtsuka T. et al. （保富）	Tenascin-C aggravates autoimmune myocarditis via dendritic cell activation and Th17 cell differentiation.	J.Am.Heart Assoc.	E-pub		2014
Ezzikouri S. et al. （小原恭子）	Inhibitory Effects of Pycnogenol® on Hepatitis C Virus Replication.	Antiviral Research	113C	93-102	2015
Tsukiyama-Kohara K. et al. （小原恭子）	Tupaia belangeri as anExperimental Animal Model for Viral Infection.	Experimental Animal	63(4)	367-74	2014
Zare-Bidaki M. et al. （小原恭子）	Toll-like receptor 4 and hepatitis B infection:molecular mechanisms and pathogenesis.	Viral Immunolgy	27	321-6	2014
Arai M. et al. （小原恭子）	Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.	Biochem Biophys Res Commun.	448	56-62	2014
Koo CX. et al. （石井）	RNA Polymerase III Regulates Cytosolic RNA:DNA Hybrids and Intracellular MicroRNAExpression.	J Biol. Chem.			2015
Temizoz B. et al （石井）	TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.	Eur J Immunol			2014
Natsuaki Y. et al. （石井）	Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin.	Nature Immunol.	15(11)	1064-9	2014

Piao Z. et al. (石井)	Protective properties of a fusion pneumococcalsurface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice.	Vaccine.	32 (43)	5607-13	2014
Uraki R. et al. (石井)	Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine.	Vaccine.	32 (41)	5295-300	2014
Mizukami T. et al. (石井)	System vaccinology for the evaluation of influenza vaccine safety by multiplex gene detection of novel biomarkers in a preclinical study and batch release test.	PLoS One.	9(7)	e101835.	2014
Hemmi M. et al. (石井)	The early activation of CD8+ T cells is dependent on type I IFN signaling following intramuscular vaccination of adenovirus vector.	Biomed Res. Int.	2014	158128	2014
Yagi M. et al. (石井)	Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.	PLoS One.	9(6)	e98460.	2014
Zhao H. et al. (石井)	Olfactory plays a key role in spatiotemporal pathogenesis of cerebral malaria.	Cell Host Microbe.	15(5)	551-63	2014
Onishi M. et al. (石井)	Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.	Vaccine.	32(25)	3004-9	2014

Imanishi T. et al. (石井)	Nucleic acid sensing by T cells initiates Th2cell differentiation.	Nature Commun.	5	3566	2014
Lam AR. et al. (石井)	RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.	Cancer Res.	74(8)	2193-2203	2014
Koo CX. et al. (石井)	RNA Polymerase III Regulates Cytosolic RNA:DNA Hybrids and Intracellular MicroRNAExpression.	J Biol. Chem.			2015
Okamoto M. et al (押海)	IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response tohepatitis C virus infection.	J. Immunol.	192	2770-2777	2014
Takaki H. et al. (押海)	Dendritic cell subsets involved in type I IFN induction in mouse measles virus infection models.	Int J Biochem Cell Biol.	53	329-333	2014
Leong CR. et al (押海)	A MAVS/TICAM-1-independent interferon-inducing pathway contributes to regulation of hepatitis B virus replication in the mouse hydrodynamic injection model.	J Innate Immun.	7	47-58	2015
Kasamatsu J. et al. (押海)	INAM plays a critical role in IFN-γ production by NK cells interacting with polyinosinic-polycytidylic acid-stimulated accessory cells.	J. Immunology	193	5199-204	2014

日下部篤宣 他 （村上）	B 型・D 型肝炎ウイルス重複感染による肝障害に対してペグインターフェロンが有効であった 1 例	肝臓		55(11)	653-660	2014
Hamada-Tsutsumi S. et al. （村上）	Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection.	PLoS ONE		10(2)	e0118062	2015
Totani H. et al. （村上）	Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.	Int. J. Hematol.	E-pub			2015
Ara MN. et al. （櫻井）	Construction of an aptamer modified liposomalsystem targeted to tumor endothelial cells.	Biological Pharmaceutical Bulletin		37(11)	1742-1749	2014
Akhter A. et al. （櫻井）	Ligand density at the surface of a nanoparticleand different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells.	International Journal of Pharmaceutics		475(1-2)	227-237	2014
Ara MN. et al. （櫻井）	An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.	Biomaterials		35(25)	7110-7120	2014
Sakurai Y. et al. （櫻井）	Improvement of doxorubicin efficacy usingliposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.	Molecular Pharmaceutics		11(8)	2713-2719	2014

Akbar SM. et al. （日浅）	Designing immune therapy for chronic hepatitis B.	J Clin. Exp. Hepatol.	4(3)	241-246	2014
Michitaka K. et al. （日浅）	Clinical features of adult patients with acute hepatitis B virusinfection progressing to chronic infection.	Int J Hepatol.	2014	358206	2014
Yamazaki T. et al. (日浅）	Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.	PLoS One	9(10)	e109123	2014
Hirooka M. et al. （日浅）	Nonalcoholic Fatty Liver Disease: Portal Hypertension Due toOutflow Block in Patients without Cirrhosis.	Radiology	274(2)	597-604	2015
Nishida N. et al. （日浅）	New susceptibility and resistance HLA-DPalleles to HBV-related diseases identified by a trans-ethnic association study in Asia.	PLoS One	9(2)	e86449	2014
Iio E. et al. （日浅）	Genome-wide association study identifies aPSMD3 variant associated with neutropenia in interferon-basedtherapy for chronic hepatitis C.	Hum Genet.	134	279-289	2015
Kuroda T. et al （日浅）	Pancreatic congestionin liver cirrhosis correlates with impaired insulin secretion.	J Gastroenterol.	E-pub		2014

Hiraoka A. et al. （日浅）	Prognosis and therapy for ruptured hepatocellular carcinoma: Problems with staging and treatment strategy.	Eur J Radiol.	84	366-371	2015
Castellaneta A. et al. （日浅）	Plasmacytoid dendritic cell-derived IFN-α promotes murine liver ischemia/reperfusion injury by inductionof hepatocyte IRF-1.	Hepatology	60	267-277	2014
Yoshida O. et al. （日浅）	DAP12 deficiency in liver allografts results in enhanced donor DC migration, augmented effector T cell responses and abrogation of transplant tolerance.	Am J Transplant.	14	1791-1805	2014

IV． 研究成果の刊行物・別刷

The RNA Sensor RIG-I Dually Functions as an Innate Sensor and Direct Antiviral Factor for Hepatitis B Virus

Seiichi Sato,[1,2,10] Kai Li,[1,2,10] Takeshi Kameyama,[1,2,10] Takaya Hayashi,[3,10] Yuji Ishida,[4] Shuko Murakami,[5] Tsunamasa Watanabe,[5] Sayuki Iijima,[5] Yu Sakurai,[6] Koichi Watashi,[7] Susumu Tsutsumi,[5] Yusuke Sato,[6] Hidetaka Akita,[6] Takaji Wakita,[7] Charles M. Rice,[8] Hideyoshi Harashima,[6] Michinori Kohara,[9] Yasuhito Tanaka,[5] and Akinori Takaoka[1,2,*]

[1]Division of Signaling in Cancer and Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
[2]Molecular Medical Biochemistry Unit, Biological Chemistry and Engineering Course, Graduate School of Chemical Sciences and Engineering, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
[3]Research Center for Infection-Associated Cancer, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan
[4]PhoenixBio Co., Ltd., Higashihiroshima, Hiroshima 739-0046, Japan
[5]Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan
[6]Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan
[7]Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan
[8]Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA
[9]Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo 156-8506, Japan
[10]Co-first author
*Correspondence: takaoka@igm.hokudai.ac.jp
http://dx.doi.org/10.1016/j.immuni.2014.12.016

SUMMARY

Host innate recognition triggers key immune responses for viral elimination. The sensing mechanism of hepatitis B virus (HBV), a DNA virus, and the subsequent downstream signaling events remain to be fully clarified. Here we found that type III but not type I interferons are predominantly induced in human primary hepatocytes in response to HBV infection, through retinoic acid-inducible gene-I (RIG-I)-mediated sensing of the 5'-ε region of HBV pregenomic RNA. In addition, RIG-I could also counteract the interaction of HBV polymerase (P protein) with the 5'-ε region in an RNA-binding dependent manner, which consistently suppressed viral replication. Liposome-mediated delivery and vector-based expression of this ε region-derived RNA in liver abolished the HBV replication in human hepatocyte-chimeric mice. These findings identify an innate-recognition mechanism by which RIG-I dually functions as an HBV sensor activating innate signaling and to counteract viral polymerase in human hepatocytes.

INTRODUCTION

Hepatitis B virus (HBV) is a hepatotropic virus of the *Hepadnaviridae* family and contains a circular, partially double-stranded DNA genome of about 3.2 k base pairs that is replicated via reverse transcription of a pregenomic RNA (pgRNA). HBV causes hepatic inflammation associated with substantial morbidity worldwide (Rehermann and Nascimbeni, 2005; Prot-

zer et al., 2012; Revill and Yuan, 2013). Around four hundred million people worldwide are persistently infected with HBV, which is a major causative factor associated with not only inflammation but also cirrhosis and even cancer of the liver. Currently, interferon (IFN) and nucleoside/nucleotide analogs are available for HBV treatment (Rehermann and Nascimbeni, 2005; Halegoua-De Marzio and Hann, 2014). However, the long-term response rates are still not satisfactory. Elucidation of host immune response against HBV infection is crucial for better understanding of the pathological processes and viral elimination to control HBV infection.

The type I IFNs, IFN-α and IFN-β, are representative cytokines that elicit host innate immune responses against viral infections. In addition, another IFN family, type III IFNs (IFN-λ, also known as IL-28 and IL-29) exhibits potent antiviral activity similar to IFN-α and IFN-β (Sheppard et al., 2003; Kotenko, 2011; Kotenko et al., 2003). Production of type I and type III IFNs is massively induced in many types of cells upon infection with various viruses, which is known to be mediated by the activation of pattern-recognition receptors (PRRs). During virus infection, virus-derived nucleic acids (both RNA and DNA) are mainly sensed by certain PRRs, such as retinoic acid-inducible gene-I (RIG-I) (Yoneyama et al., 2004; Choi et al., 2009; Chiu et al., 2009; Ablasser et al., 2009), melanoma differentiation-associated gene 5 (MDA5) (Yoneyama et al., 2005), cyclic GMP-AMP synthase (cGAS) (Sun et al., 2013), and IFN-γ-inducible protein 16 (IFI16) (Unterholzner et al., 2010). Particularly, RIG-I is a key PRR that can detect virus-derived RNAs in the cytoplasm during infection with a variety of viruses, such as influenza virus, hepatitis C virus (HCV), and measles virus, which are closely related to human disease pathogenesis (Rehwinkel and Reis e Sousa, 2010). Binding of RIG-I to its ligand RNAs, such as 5'-triphosphorylated RNA or short double-stranded RNAs (Takeuchi and Akira, 2009; Hornung et al., 2006), activates the downstream signaling pathways in a manner dependent on the adaptor protein mitochondrial antiviral

signaling protein (MAVS; also known as IPS-1, VISA, or Cardif) (Takeuchi and Akira, 2009), leading to the induction of the IFN-regulatory factor-3 (IRF-3) and NF-κB-dependent gene expression and the subsequent production of type I and type III IFNs and inflammatory cytokines (Takeuchi and Akira, 2009). Thus, RIG-I sensing of viral RNA is a crucial process to activate the antiviral innate responses to limit viral replication and the activation of adaptive immunity (Takeuchi and Akira, 2009).

As for the viruses that are known to be the leading cause of hepatic inflammation, RIG-I is the major PRR that initiates innate immune responses against HCV. RIG-I sensing of HCV is mediated through its recognition of the poly-U/UC motif of the HCV RNA genome 3′ nontranslated region, which leads to the activation of type I IFN response (Saito et al., 2008). On the other hand, earlier studies have shown that the innate immune activation is impaired and the induction of type I IFNs such as IFN-α or IFN-β is hardly detected in animal models of HBV infection, as compared with HCV infection (Wieland et al., 2004; Nakagawa et al., 2013). However, it is still not fully clarified how HBV is recognized by human hepatocytes and the role of type III IFNs as well.

Here we report that HBV infection predominately induces type III, but not type I, IFN gene induction, which is mediated by RIG-I through its recognition of the 5′-ε region of HBV-derived pgRNA. We also show that RIG-I can counteract the interaction of HBV polymerase (P protein) with the 5′-ε region of pgRNA in an RNA-binding dependent manner, resulting in the suppression of HBV replication. Furthermore, liposome-mediated delivery and expression of the 5′-ε region-derived RNA in liver suppressed the HBV replication in vivo in chimeric mice with humanized livers. Thus, our findings demonstrate the innate defense mechanisms based on the viral RNA-RIG-I interaction, whereby RIG-I functions not only as a HBV sensor for the activation of IFN response but also as a direct antiviral factor.

RESULTS

Type III IFNs Are Predominantly Induced in Hepatocytes during HBV Infection

To investigate the innate immune activation during HBV infection, we examined type I and type III IFN responses in human hepatocytes. Consistent with the previous reports (Wieland et al., 2004; Nakagawa et al., 2013), we hardly observed the induction of type I IFNs, IFN-α4, and IFN-β in response to transfection with plasmids carrying 1.24-fold the HBV genome of three major different genotypes, Ae (HBV-Ae), Bj (HBV-Bj), and C (HBV-C) (Figure 1A and Figure S1A available online) at least up to seven days after transfection, although the expression of HBV RNAs was detectable (Figure S1B). On the other hand, type III IFN, IFN-λ1, was induced in all of the three types of human hepatocyte cell line tested (Figures 1A and S1A). In HepG2 cells, HBV-C shows the highest IFN-λ1 response, which was also confirmed by ELISA, albeit weakly (Figures 1A and 1B). Moreover, IFN-λ1 in culture supernatant could inhibit vesicular stomatitis virus (VSV) replication in plaque reduction assay, as well as HBV replication (Figure S1C), indicating the physiological relevance of the induced IFN-λ1 to antiviral activities. Consistent with these results, we observed the significant induction of not only IFN-λ1 but also IFN-λ2 and -λ3 in primary human hepato-

cytes (PHH) in vitro 24 hr after infection with HBV-C (Figure 1C); however, neither of type I nor type II IFN tested was induced (Figures S1D and S1E). Although it is difficult to simply compare the amount of IFN induced by different types of virus, the induction of IFN-λ1, λ2, and λ3 mRNAs in response to HBV infection was much weaker than that of Newcastle disease virus (NDV) infection (Figure 1C). In this regard, in order to rule out the possibility that the IFN-λ response is due to contaminants in the inocula, we used Lamivudine (LAM), an HBV inhibitor, in this assay. Treatment with LAM inhibited IFN-λ mRNA induction in response to HBV infection in PHH (Figure 1C), suggesting that the IFN response is actually induced by HBV replication. Furthermore, we analyzed HepG2-sodium taurocholate cotransporting polypeptide (NTCP)-C4 cell line (Iwamoto et al., 2014) stably expressing human NTCP, a functional receptor for HBV (Yan et al., 2012), and confirmed that IFN-λ1 and IFN-inducible genes such as OAS2 and RSAD2, but not IFN-β, were induced in these cells after infection with HBV-C, and that these inductions were abolished by treatment with LAM (Figure 1D). To next assess the innate immune responses in vivo during HBV infection, we exploited severe combined immunodeficiency mice that carry the urokinase-type plasminogen activator transgene controlled by an albumin promoter (uPA$^{+/+}$/SCID mice), in which more than 70% of murine hepatocytes were replaced by human hepatocytes (Tateno et al., 2004) (hereinafter referred to as chimeric mice). After the chimeric mice were intravenously infected with HBV-C, which was derived from patients with chronic hepatitis, the expression of type III IFN mRNAs increased in the liver tissue, whereas IFN-α4 and IFN-β mRNAs were not upregulated (Figure 1E). In parallel with this type III IFN response, we also observed the expression of IFN-inducible genes, such as CXCL10, OAS2, and RSAD2, in the human liver of these infected mice (Figure 1E). These findings indicate that a moderate type III but not type I or type II IFN response is activated in human hepatocytes in response to HBV infection.

HBV-Induced Type III IFN Expression Depends on RIG-I

We next determined which sensor-mediated signaling pathway is responsible for the HBV-induced type III IFN response. As HBV is a DNA virus (Rehermann and Nascimbeni, 2005; Protzer et al., 2012; Revill and Yuan, 2013), we assessed the contribution of previously reported cytosolic DNA sensors including RIG-I (Chiu et al., 2009; Ablasser et al., 2009; Choi et al., 2009), IFI16 (Unterholzner et al., 2010), and cGAS (Sun et al., 2013) in human hepatocytes. Knockdown analyses revealed that IFN-λ1 induction in HepG2 or Huh-7 cells by plasmid transfection for HBV-C or HBV-Ae, respectively, was suppressed by the knockdown of RIG-I, but not that of the other sensors (Figures 2A, S2A and S2B). To further confirm the involvement of RIG-I in HBV-triggered type III IFN response, we measured IFN-λ1 mRNA expression induced by plasmid expression in Huh-7.5 cells that carry a dominant-negative mutant RIG-I allele that prevents RIG-I signaling (Saito et al., 2007), as compared with Huh-7 cells that have an intact RIG-I pathway. Huh-7.5 cells failed to induce IFN-λ1 mRNA expression in response to HBV-Ae genome plasmid transfection, as in the case of stimulation with 5′-triphosphate RNA (3pRNA), a RIG-I ligand (Takeuchi and Akira, 2009; Hornung et al., 2006) (Figure 2B). In concordance with this result, knockdown of tripartite motif containing protein

CellPress

Figure 1. IFN-λ Induction in Human Hepatocytes in Response to HBV Infection

(A) Quantitative RT-PCR (qRT-PCR) analysis of *IFNL1* (left), *IFNA4* (middle), and *IFNB1* (right) mRNA at the indicated times after transfection with 1.24-fold the HBV genome (genotype Ae, Bj, or C) or empty vector (Mock) in HepG2 cells.

(B) ELISA of IFN-λ1 at 48 or 72 hr after transfection with the HBV genome in HepG2 cells. The dot line indicates the minimum detectable amount (31.2 pg/ml) of IFN-λ1 by the ELISA kit. ND, not detected, indicates below the minimum detectable amount.

(C) qRT-PCR analysis of *IFNL1*, *IFNL2*, and *IFNL3* mRNA at 24 hr after infection with HBV, NDV (multiplicity of infection = 10) or mock (−), or media-treated Lamivudine (LAM) as control in primary human hepatocytes (PHH). The mRNA copy number (±SD) of each subtype of type III IFN per 1 μg total RNA upon HBV-C infection is as follows: *IFNL1* (83,197.6 ± 6,241.4) and *IFNL2/3* (409,280.6 ± 119,676.2).

(D) Time course analyses by qRT-PCR of *IFNL1*, *OAS2*, *RSAD2*, *IFNB1* mRNA, and *pgRNA* at the indicated times after HBV infection in HepG2-hNTCP-C4 cells. The effect of Lamivudine treatment was also analyzed.

(E) qRT-PCR analysis of *IFNL1*, *IFNL2*, *IFNL3*, *IFNA4*, *IFNB1*, *CXCL10*, *OAS2*, and *RSAD2* mRNA of liver tissues at 4 or 5 weeks after infection with HBV-C in chimeric mice. (−), uninfected mice. Red lines represent the mean of each dataset. *p < 0.05 and **p < 0.01 versus control. RE, relative expression. (A–D) Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. See also Figure S1.

25 (TRIM25), MAVS, TANK-binding kinase 1 (TBK1), and IRF-3, all of which are signaling molecules essentially involved in the RIG-I-mediated IFN pathway (Takeuchi and Akira, 2009), re-

sulted in the suppression of IFN-λ1 mRNA induction in HepG2 cells in response to transfection with the HBV-C genome. On the other hand, such an effect was not observed in cells treated

Immunity *42*, 1–10, January 20, 2015 ©2015 Elsevier Inc. 3

**A**

B

C

D

Figure 2. RIG-I-Dependent IFN-λ Induction in Response to HBV Infection

(A) HepG2 cells treated with control siRNA (Control) or siRNA targeting RIG-I, IFI16, or cGAS were transfected with the HBV-C genome for 48 or 72 hr. The amount of IFN-λ1 were measured by ELISA. The dot line indicates the minimum cytokine expression detected (31.2 pg/ml) of IFN-λ1 by the ELISA kit. ND, not detected, indicates below detectable concentrations (left), and knockdown efficiency was analyzed by immunoblotting (IB) (right).

(B) qRT-PCR analysis of *IFNL1* mRNA in Huh-7 or Huh-7.5 cells transfected with the HBV-Ae genome (at 24 hr after transfection) or stimulated with 3pRNA (1 μg/ml) for 6 hr.

(C) HepG2 cells treated with control siRNA (Control) or the indicated siRNAs were transfected with the HBV-C genome. At 48 hr after transfection, total RNAs were subjected to qRT-PCR analysis for *IFNL1*.

(D) qRT-PCR analysis of *IFNL1* mRNA in siRNA-treated PHH at 24 hr postinfection with indicated HBV genotype. Mock, empty vector-transfected. (−), uninfected. Data were normalized to the expression of *GAPDH*. Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. *p < 0.05 and **p < 0.01 versus control in (B) or HBV-infected control group in (A, C, and D). NS, not significant. See also Figure S2.

with either TRIF (also known as TICAM-1) or MYD88 siRNA (Figures 2C and S2C). In addition, we confirmed that the knockdown of RIG-I and MAVS abolished IFN-λ1 induction in PHH infected with each genotype (Figure 2D). Furthermore, we also confirmed by knockdown assay that the induction of IFN-λ1 and OAS2 mRNA in HepG2-hNTCP-C4 cells in response to infection with HBV-C was dependent on RIG-I (Figure S2E). These data indicate that IFN-λ1 gene induction during HBV infection depends largely on RIG-I signaling pathway.

The 5′-ε Region of HBV pgRNA Is a Key Element for RIG-I-Dependent IFN-λ1 Induction

RIG-I can recognize not only virus-derived RNA but also DNA in the cytoplasm (Yoneyama et al., 2004; Choi et al., 2009; Chiu et al., 2009; Ablasser et al., 2009). To further clarify how RIG-I recognizes HBV, we first examined either or both of which nucleic acid (DNA and RNA) derived from HBV-infected cells can activate IFN-λ1 gene expression. Transfection with nucleic acid fractions extracted from HBV infected Huh-7 cells after pretreatment with RNase A, but not DNase I resulted in marked inhibition of the *IFNL1* promoter activation, suggesting that virus-derived RNAs might be candidates of the RIG-I ligand during HBV infection (Figure 3A).

The HBV genome comprises a partially double-stranded 3.2 kb DNA. During a life cycle of HBV in hepatocytes, its covalently closed circular DNA (cccDNA) is transcribed to generate four major RNA species: the 3.5, 2.4, 2.1, and 0.7 kb viral RNA transcripts (Rehermann and Nascimbeni, 2005; Protzer et al., 2012; Revill and Yuan, 2013). We created an siRNA to suppress

the expression of all of these RNA transcripts and tested its effect on HBV-induced IFN-λ1 expression. As shown in Figure 3B, knockdown with this siRNA (Figure S3A) suppressed IFN-λ1 induction in Huh-7 cells transfected with HBV-Ae. Next, to determine which of these HBV RNA transcripts is/are involved in the RIG-I-mediated IFN-λ1 induction, we prepared expression vectors to express each of these four viral transcripts in HEK293T cells that are often used to analyze RIG-I signaling pathway in human cells. As a result, it is only the longest 3.5 kb transcript, that is, pgRNA, that has the potential to elicit a significant induction of IFN-λ1 mRNA (Figures 3C and S3B). It was also confirmed by knockdown analysis with pgRNA-targeted siRNA, which showed significant suppression of IFN-λ1 induction in HepG2 cells transfected with HBV-Ae (Figure S3C). These results suggest that 5′-1.1 kb region of HBV pgRNA is critical for the activation of RIG-I pathway to induce IFN-λ1 expression. On the other hand, the remaining three transcripts, which also contain the same sequence of part of this 1.1 kb region of HBV pgRNA at the 3′ end of their transcripts, failed to induce IFN-λ1 mRNA (Figure 3C). An artificially deleted form of pgRNA, which lacks this overlapping sequence at the 3′-region (Δ3), showed IFN-λ1 induction, whereas such response was not observed for another mutant pgRNA lacking it at the 5′-region (Δ5) (Figure 3D). These data also support a possible important role of the 5′-overlapping sequence of HBV pgRNA for RIG-I-mediated IFN-λ1 induction.

The 5′-end of HBV pgRNA is known to contain the encapsidation sequence, called "epsilon (ε)," which takes a stem-loop secondary structure (Junker-Niepmann et al., 1990; Pollack and

CellPress

Figure 3. RIG-I Activation Is Mediated by Its Recognition of the 5′-ε Region of HBV pgRNA

(A) Luciferase activity of an IFN-λ1 reporter plasmid after 24 hr of stimulation with nucleic acids (2 μg/ml) extracted from Huh-7 cells transfected with control plasmid (Mock) or the HBV-Ae genome with or without RNase A or DNase I treatment. RLU, relative luciferase units.

(B) Huh-7 cells treated with control or HBV RNA-targeted siRNA were transfected with the HBV-Ae genome or mock. After 24 hr of transfection, total RNAs were subjected to qRT-PCR for IFNL1.

(C and D) A schematic representation of four types of HBV RNAs, pgRNA (3.5 kb), 2.4 kb, 2.1 kb, and 0.7 kb RNAs in (C), and two deleted forms of pgRNA, Δ5 and Δ3, in (D). The overlapping region is shown in blue. qRT-PCR analysis of IFNL1 mRNA of HEK293T cells after 24 hr of transfection with the indicated expression vectors. Data were normalized to the amount of each HBV RNA expression (C and D).

(E) A schematic representation of pgRNA, εRNA, or control RNA (ContRNA) (left). HEK293T cells treated with control or RIG-I siRNA were unstimulated (Mock) or stimulated with εRNA for 12 hr. Total RNAs were subjected to qRT-

PCR for IFNL1 (middle). qRT-PCR analysis of IFNL1 mRNA in HEK293T cells after 12 hr of stimulation with εRNA or ContRNA (right). Each of the RNAs was prepared by in vitro transcription.

(F) HEK293T cells were transfected with each plasmid for stem-loop mutants of pgRNA (5STM, 3STM, or 5 and 3STM), and then subjected to qRT-PCR analysis as described in (C). *p < 0.05 and **p < 0.01 versus control in (A, B, and E) or versus 3.5K in (C, D, and F). NS, not significant. See also Figure S3.

Ganem, 1993; Knaus and Nassal, 1993; Jeong et al., 2000). Therefore, we hypothesized that this 5′-ε structure might confer a possible pathogen-associated molecular pattern (PAMP) motif for RIG-I recognition. To test this hypothesis, we stimulated HEK293T and HepG2 cells with the ε region-derived RNA (hereafter called εRNA). Consequently, IFN-λ1 mRNA was significantly induced, which was dependent on RIG-I, while such a response was not detected upon stimulation with the equivalent length of RNA that is derived from HBV pgRNA but does not contain any ε element (ContRNA) (Figure 3E and S3D). We also confirmed RIG-I-dependent IRF-3 activation in response to stimulation with εRNA (Figures S3D and S3E). Due to the overlapping sequence of 5′- and 3′-ends of HBV pgRNA as mentioned above, this ε element is found at both ends of pgRNA. We next generated several mutant forms of HBV pgRNA, each of which carries mutations within 5′- or 3′-ε region or both to disrupt the stem-loop structure (5STM, 3STM, or 5 and 3STM, respectively). In concordance with the results shown in Figures 3C and 3D and S3B, IFN-λ1 mRNA induction was detected upon expression of the 3STM transcript that has an intact 5′-ε region, as similar to that of intact 3.5-kb pgRNA (Figure 3F). In contrast, either 5STM or 5 and 3STM did not show significant response. These findings indicate that the 5′-ε region of HBV pgRNA is critical for IFN-λ1 induction possibly through the recognition by RIG-I.

RIG-I Interacts with the ε-Region of pgRNA

Next, we assessed the interaction of RIG-I with the ε region of HBV pgRNA, that is, εRNA. Pull-down assays showed that Flag-tagged RIG-I was coprecipitated with εRNA, but not with

ContRNA, in HEK293T cells (Figure 4A, top). Similarly, endogenous RIG-I interacted with εRNA albeit weakly (Figure 4A, bottom). We also demonstrated the intracellular colocalization of RIG-I with εRNA in Huh-7.5 cells (Figure 4B). In addition, RNA-binding protein immunoprecipitation (RIP) assay revealed that the full length of HBV pgRNA was detected in the RIG-I-immunoprecipitated complex, and Δ5 pgRNA and Δ3 pgRNA were also detected (Figure S4A), which is seemingly inconsistent with the results by the functional assay (Figures 3C, 3D, 3F and S3C). These results suggest that the ε region is required for its interaction with RIG-I, but only the 5′-ε region is necessary to activate RIG-I pathway. We further tried to determine which region of RIG-I mediates its interaction with HBV pgRNA. Both RIP assay and RNA pull-down assay with several deletion mutants of RIG-I showed that the C-terminal portion of RIG-I (C-RIG) including its helicase domain and repressor domain (RD) except for CARDs can bind to HBV pgRNA (Figure 4C; Figures S4B and S4C). In addition, gel shift assay showed that the interaction of HBV εRNA or pgRNA was impaired with the RD or C-RIG mutant, respectively, each of which carries a point mutation (K888E) that abolishes its RNA-binding activity (Cui et al., 2008) (Figure 4D). A similar result was also obtained by RIP assay, wherein the wild-type (WT) C-RIG, but not the K888E mutant, was coimmunoprecipitated with HBV pgRNA (Figure S4D), like HCV RNA that was previously reported to interact with RIG-I (Figure S4E). We also confirmed the interaction of HBV pgRNA with endogenous RIG-I in HepG2 cells, whereas its interaction with other nucleic acid sensors, such as IFI16 and MDA5 (Yoneyama et al., 2005), was not detected (Figure 4E). These data indicate that

Figure 4. RIG-I Interacts with the ε Region of pgRNA

(A) RNA pull-down assay showing the binding activity of the indicated RNAs to Flag-tagged RIG-I (Flag-RIG-I) in HEK293T cells (top) or endogenous RIG-I in HepG2 cells (bottom).

(B) FRET analysis for the interaction of YFP-tagged RIG-I (YFP-RIG-I) with rhodamine (ROX)-conjugated εRNA (εRNA-ROX) or ContRNA (ContRNA-ROX). Representative fluorescence images of YFP, ROX, and FRET^C/YFP (the ratio of corrected FRET (FRET^C) to YFP). Arrowheads indicate area showing high FRET efficiency. Scale bar represents 20 μm. Right, dot plot of FRET^C/YFP ratio (small horizontal bars, mean).

(C) RIP assay with HEK293T cell lysates expressing several Flag-tagged deletion mutants of RIG-I and pgRNA expression vector by using anti-Flag antibody. Immunoprecipitated pgRNA was quantitated by qRT-PCR and normalized to the amount of immunoprecipated proteins (Figure S4C) and is represented as fraction of input RNA prior to immunoprecipitation (percentage input).

(D) Gel-shift analysis of complex formation between εRNA and recombinant RIG-I RD (WT) or RD (K888E). Arrowheads denote position of unbound RNA and RNA–RIG-I complexes.

(E) RIP assay with HepG2 cell lysates prepared after 48 hr of transfection of the HBV-C genome by using anti-RIG-I, anti-IFI16, anti-MDA5, or control immunoglobulin G. The immunoprecipitated pgRNA was measured by qRT-PCR (top) as described in (C). Whole-cell expression and immunoprecipitated amounts of RIG-I, IFI16, and MDA5 (bottom). Data are presented as mean and SD (n = 3) and are representative of at least three independent experiments. $^*p < 0.05$ and $^{**}p < 0.01$ versus control in (B and E). NS, not significant. See also Figure S4.

the 5′-ε region of viral pgRNA functions as an HBV-associated molecular pattern to be specifically recognized by RIG-I and can trigger IFN-λ response.

RIG-I Exerts an Antiviral Activity by Counteracting the Interaction of HBV Polymerase with pgRNA

We next assessed the contribution of RIG-I pathway in antiviral defense against HBV infection. RIG-I knockdown in PHH resulted in a higher HBV genome copy number at 10 days after infection with HBV-C, as compared with PHH treated with control siRNA (Figure 5A). A similar observation was made for RIG-I siRNA-treated HuS-E/2 cells (Figure S5A). These results indicate an implicated role of RIG-I as an innate sensor to activate antiviral response against HBV infection. On the other hand, it has been previously reported that the 5′-ε region of HBV pgRNA is important to serve as a binding site of viral P protein for initiating reverse transcription (Bartenschlager and Schaller, 1992). As consistent with this, we showed that the P protein interacts with εRNA in Huh-7.5 and HEK293T cells, by fluorescence resonance energy transfer (FRET) analysis (Figure 5B) and RNA pull-down assay (Figure S5B), respectively. These findings facilitated us to examine whether RIG-I could block the access of P protein toward the ε region. As we expected, recombinant RIG-I protein suppressed the interaction of P protein with pgRNA in a dose-dependent manner (Figure 5C). Such an inhibitory effect was also observed in Huh-7.5 cells by expression of WT RIG-I, as well as its T55I (Sumpter et al., 2005; Saito et al., 2007) or K270A (Takahasi et al., 2008) mutant (Figures 5D and S5C), both of which are not able to induce ligand-dependent activation of the downstream signaling but retain their RNA-binding activities. On the other hand, the

K888E (Cui et al., 2008) mutant could not inhibit the binding of P protein with pgRNA (Figures 5D and S5C). In addition, treatment with recombinant IFN-λ1 in Huh-7.5 cells upregulated the amount of the mutant RIG-I protein (T55I) (Figure S5D), resulting in a partial inhibition of the P protein interaction with pgRNA, and this inhibitory effect was abrogated by RIG-I knockdown (Figure 5E). In fact, FRET analysis showed that the P protein-εRNA interaction was significantly suppressed by expression of the RIG-I RD (WT) alone, but not the mutant RD (K888E) (Figure S5E). Furthermore, HBV replication was also suppressed by expression of the RIG-I RD (WT) in Huh-7.5 cells, wherein any IFN induction is not observed, while the mutant RD (K888E) did not affect viral replication (Figure 5F). These findings revealed another aspect of RIG-I as a direct antiviral factor through its interference with the binding of HBV P protein to pgRNA in an IFN pathway-independent manner.

The εRNA Restricts HBV Replication in Human Hepatocyte-Chimeric Mice

Lastly, based on the above results, we tried to harness the therapeutic potential of the P protein-interacting εRNA for the control of HBV infection. A vector was designed to include a 63 bp DNA oligo, which is transcribed into an εRNA. We confirmed in the in vitro experiments using Huh-7.5 cells that εRNA induced by this vector-driven expression is capable to function as a decoy RNA to interfere with the binding of HBV P protein to pgRNA and to inhibit viral replication in an IFN-independent manner (Figures 6A and 6B, left). On the other hand, εRNA did not show any difference in HCV replication as compared with control (Figure 6B, right). In order to evaluate the therapeutic efficacy of εRNA in vivo, we exploited HBV infection model of human

CellPress

Figure 5. RIG-I Functions as an Antiviral Factor by Counteracting the Interaction of HBV P Protein with pgRNA

(A) qPCR analysis of copy numbers of encapsidated HBV DNA (left) and qRT-PCR analysis of *RIG-I* (middle) and *IFNL1* mRNA (right) in control or RIG-I siRNA-treated PHH after 10 days of infection with HBV-C.

(B) FRET analysis for the interaction between YFP-tagged P protein (YFP-P) or YFP and εRNA-ROX as described in Figure 4B. Scale bar represents 20 μm. Arrowheads indicate area showing high FRET efficiency.

(C) HEK293T cell lysates expressing pgRNA and HA-tagged P protein (HA-P) were incubated with the indicated amount of recombinant RIG-I (rRIG-I). The interaction of pgRNA with HA-P was analyzed by RIP assay and qRT-PCR analysis as described in Figure 4C.

(D) Cell lysates from Huh-7.5 cells expressing HBV pgRNA, HA-P, and Flag-RIG-I or its mutants as indicated were subjected to RIP assay for the characterization of the capability of RIG-I to counteract the interaction of pgRNA with HA-P, as described in Figure 4C.

(E) The effect of rIFN-λ1 treatment on the interaction of pgRNA with HA-P in Huh-7.5 cells was assessed by RIP assay. Huh-7.5 cells expressing both pgRNA and HA-P were treated with rIFN-λ1 (100 ng/ml) for 24 hr, and subjected to RIP assay as described in Figure 4C. RIG-I dependency was also determined by RIG-I knockdown analysis.

(F) Huh-7.5 cells were transfected with an expression vector for RIG-I RD (WT) or RD (K888E), together with the HBV-Ae genome. After 72 hr of transfection, copy numbers of encapsidated HBV DNA were measured (left), as described in (A). Expression of Flag-RIG-I RD (WT) and RD (K888E) (right). *p < 0.05 and **p < 0.01 versus control. NS, not significant. See also Figure S5.

hepatocyte-chimeric mice. HBV-infected mice underwent intravenous administration with the εRNA expression vector loaded in a liposomal carrier, a multifunctional envelope-type nanodevice (MEND) for efficient delivery, for 2 weeks. Treatment with εRNA-MEND significantly suppressed the elevation of the number of viral genome copies in the sera by less than one tenth of those for control mice (Figure 6C). Consistently, immunofluorescence analyses showed that the expression of HBV core antigen (HBcAg) in the liver tissues of εRNA-MEND-treated chimeric mice was remarkably reduced as compared with those of control mice (Figure 6D).

DISCUSSION

The innate immune system acts as a front line of host defense against viral infection. In this step, PRRs play a crucial role in the recognition of invading viruses. In particular, nucleic acid sensing of viruses is central to the initiation of antiviral immune responses. In this study, we tried to seek for a relevant nucleic acid sensor(s) for HBV and to characterize the IFN response during HBV infection. As a result, we have identified RIG-I as an important innate sensor of HBV to predominantly induce type III IFNs in hepatocytes through its recognition of the 5′-ε stem-

loop of HBV pgRNA (Figures 1, 2, 3, and 4). In this respect, there have also been several reports showing that HBV X or P protein interacts with MAVS or competes for DDX3 binding with TBK1, respectively (Wei et al., 2010; Wang and Ryu, 2010; Yu et al., 2010), and inhibits RIG-I-mediated type I IFN pathway, which possibly enables HBV to evade from antiviral innate immune response. This would mirror the important role of RIG-I-mediated signaling for antiviral defense against HBV infection, although further investigation will be required to determine whether other sensing molecules except for RIG-I are engaged in the activation of innate responses in other cell types including dendritic cell subsets. Interestingly, Lu et al. have recently showed that the genotype D of HBV is sensed by MDA5, but not RIG-I, which is based only upon the analyses with HBV genome (2-fold) plasmid transfection in a single cell line Huh-7 (Lu and Liao, 2013). In this respect, we presume that such seemingly contradictory results might arise mainly from the difference in HBV genotype: It has been reported that the genotype D is phylogenetically different from the genotypes A, B, and C, which we analyzed in this study (Kato et al., 2002).

In addition, according to our results (Figure 1C and S1C), HBV-induced type III IFN response does not seem to be efficient as compared with the case with NDV infection. We speculate that